---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-072356"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:41:43.292521+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Autolus Therapeutics VP Finance resigns; CFO Dolski appointed PAO

## Summary
- Andrew Mercieca resigned as VP Finance & PAO on Feb 24, 2025, effective August 2025; not due to any disagreement.
- CFO Rob Dolski appointed principal accounting officer effective April 3, 2025, in addition to his CFO role.
- No additional compensation for Dolski for the added PAO duties; no family or transaction disclosures.
- Mercieca's resignation follows a statutory three-month minimum notice period under UK law.

## SEC filing metadata
- accession: 0001193125-25-072356
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/0001193125-25-072356-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/d945856d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-072356
- JSON: https://secwatch.observer/filing/0001193125-25-072356.json
- Plain text: https://secwatch.observer/filing/0001193125-25-072356.txt

## Key facts
- Executive change
  Rob Dolski was appointed as principal accounting officer at Autolus Therapeutics plc.
  - Action: appointed
  - Role: principal accounting officer
  source text: On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/0001193125-25-072356-index.htm
- Executive change
  Andrew Mercieca resigned as Vice President of Finance and principal accounting officer at Autolus Therapeutics plc.
  - Action: resigned
  - Role: Vice President of Finance and principal accounting officer
  source text: On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/0001193125-25-072356-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.